Self-Assessment Study Program SASP (2015)
The SASP is the AUA’s most popular study tool for exam preparation! To meet your learning preference, the SASP is available in three convenient formats—booklet, online, and the innovative Q-Stream format which sends questions directly to your smartphone, computer or tablet. Pricing will be displayed upon format selection. Offering up to 20 AMA PRA Category 1 Credits™.
For almost 40 years, the AUA's Self-Assessment Study Program (SASP) has been a leading educational resource for urologists-in-training and practicing urologists. Developed each year, the SASP is a 150-question, multiple-choice practice examination that addresses the core curriculum of medical knowledge and latest advances in patient care. The SASP may be taken open or closed book, and provides correct answers with detailed answer rationales, and scientific references.
Why is the SASP the AUA's most popular study tool for exam preparation?
Constructed in the same style as the AUA and ABU's multiple-choice examinations—and offered in three convenient formats to meet your unique study preference—SASP is the AUA's most popular study tool for exam preparation. SASP provides participants their scores, the average scores of their peers, and access to answer commentary and scientific references, allowing participants to evaluate their strengths and weaknesses in various clinical areas and enrich their learning experience. Also, it is important to note that 20 – 30 percent of the content of the ABU Recertification Examination comes directly from SASP!
Offering up to 20 AMA PRA Category 1 Credits™, the SASP also helps to fulfill the CME requirements mandated by the ABU Maintenance of Certification (MOC)© process.
- Board Candidates
- Advanced Practice Providers
- Physician Assistants
After completing this activity, learners will be able to:
- Assess their knowledge of urology
- Demonstrate an increased knowledge base of urology
- Apply increased knowledge to improve the quality of patient care
- Evaluate strengths and weaknesses in urology upon review of their personalized participant profile
- Develop a personalized study program to improve their foundation of knowledge
- Discuss core knowledge of urology necessary for the ABU's Qualifying and Recertification Examinations
ABU/AUA Examination Committee Credentials and Disclosures
Christopher L. Amling, MD John Barry Professor and Chair, Department of Urology, Oregon Health & Science University. Janssen (Consultant/Advisor).
Joseph G. Borer, MD Assistant Professor of Surgery, Harvard Medical School, Associate in Urology, Department of Urology, Co-Director, Center for Robotic Surgery, Director, Center for Exstrophy, Director, Neurourology, Boston Children's Hospital, Boston, Massachusetts. No Disclosures.
Wade Bushman, MD, PhD Robert and Delores Schnoes Professor of Urology, Department of Urology, University of Wisconsin Medical School. No Disclosures.
Mark P. Cain, MD Professor of Urology, Department of Urology, Indiana University School of Medicine, Chief, Pediatric Urology, Riley Hospital for Children at IU Health. No Disclosures.
Anthony A. Caldamone, MD Professor of Surgery (Urology) and Pediatrics, The Warren Alpert School of Medicine of Brown University, Urology Residency Program Director, Head Section of Pediatric Urology, Hasbro Children’s Hospital. No Disclosures.
Steven C. Campbell, MD, PhD Professor of Surgery, Urology Residency Program Director, Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic. Pfizer (Consultant/Advisor, Scientific Study/Trial); GSK (Scientific Study/Trial); Pfizer (Meeting Participant/Lecturer).
Donna M. Connelly, BS AUA Program Coordinator. No Disclosures.
Raymond A. Costabile, MD Senior Associate Dean for Clinical Strategy, Jay Y. Gillenwater Professor of Urology and Vice Chairman, Urology Department, University of Virginia. Lilly/Icos (Consultant/Advisor, Scientific Study/Trial); Vivus (Scientific Study/Trial).
Kimberly N. Forde, BS AUA Education Coordinator. No Disclosures.
David A. Ginsberg, MD Associate Professor of Urology, Keck School of Medicine of USC, Chief of Urology, Rancho Los Amigos National Rehabilitation Center. Allergan (Consultant/Advisor, Meeting Participant/Lecturer); Allergan, Medtronic (Scientific Study/Trial).
Chris M. Gonzalez, MD, MBA Professor of Urology, Director of Genitourinary Reconstruction and Prosthetics, Feinberg School of Medicine, Northwestern University. Coloplast, American Medical Systems, Aurasense (Investment Interest).
Jeffrey M. Holzbeierlein, MD The John W. Weigel Endowed Professor of Urology, Director, Division of Urologic Oncology and Clinical Research, Department of Urology, University of Kansas Hospital. Janssen (Consultant/Advisor, Meeting Participant/Lecturer).
Douglas A. Husmann, MD Anson L Clark, Professor of Urology, Department of Urology, Mayo Clinic, Rochester, MN. No Disclosures.
Andrew T. Jones, PhD Psychometrician, American Board of Surgery. No Disclosures.
Mohit Khera, MD, MBA, MPH Associate Professor of Urology, Division of Male Reproductive Medicine and Surgery, Baylor College of Medicine. Merck, Auxilium/Slate Pharmaceuticals/MEDA, Coloplast (Consultant/Advisor, Meeting Participant/Lecturer); Endo/American Medical Systems (Consultant/Advisor, Meeting Participant/Lecturer, Scientific Study/Trial); Sprout (Investment Interest); Sexual Medicine Society of North American (Leadership Position); Lilly (Meeting Participant or Lecturer); Allergan (Scientific Study/Trial); Journal of Sexual Medicine (Health Publishing).
Tracey L. Krupski, MD Content Review Chair, AUA. No Disclosures.
Kathleen C. Kobashi, MD Head, Section of Urology and Renal Transplantation; Program Director, Urology Residency, Virginia Mason Medical Center; Fellowship Director, Pelvic Floor Medicine and Reconstructive Surgery; Allergan (Consultant/Advisor, Meeting Participant/Lecturer); Medtronic (Consultant/Advisor); Astellas (Meeting Participant/Lecturer).
Thomas F. Kolon, MD Associate Professor of Urology/Surgery, Division of Urology, University of Pennsylvania School of Medicine, Pediatric Urology Fellowship Program Director, Children’s Hospital of Philadelphia. NIH (Scientific Study/Trial).
Gary E. Lemack, MD Professor of Urology and Neurology, Rose Mary Haggar Professor Residency Program Director in Urology, Department of Urology, University of Texas Southwestern Medical Center. Astellas (Meeting Participant/Lecturer); Allergan (Consultant/Advisor, Meeting Participant/Lecturer); Afferent Pharmaceuticals, NIDDK/NIH (Scientific Study/Trial); Ferring (Consultant/Advisor).
Daniel W. Lin, MD Chief of Urologic Oncology, Professor, Department of Urology, Bridges Endowed Professorship in Prostate Cancer Research, University of Washington. Dendreon, Myriad (Consultant/Advisor, Meeting Participant/Lecturer); GenProbe (Consultant/Advisor, Scientific Study/Trial); Genomic Health, NIH/NCI, Department of Defense, Veteran’s Affairs (Scientific Study/Trial).
Brian R. Matlaga, MD, MPH Associate Professor of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine. Boston Scientific (Consultant/Advisor).
Elspeth M. McDougall, MD, FRCSC, MHPE Chair, AUA Office of Education. No Disclosures.
Ajay K. Nangia, MD Professor of Urology, Director of Andrology: Male Infertility, Microsurgery, Men's Health, Dept of Urology, University of Kansas Hospital and Medical Center. No Disclosures.
Raj S. Pruthi, MD Professor, Chair, Department of Urology, The University of North Carolina at Chapel Hill. Photocure (Consultant/Advisor).
Li-Ming Su, MD David A. Cofrin Professor of Urology, Associate Chairman of Clinical Affairs, Chief, Division of Robotic and Minimally Invasive Urologic Surgery, Department of Urology, University of Florida College of Medicine. Lippincott Williams & Wilkins, Elsevier, John Wiley & Sons, Springer (Health Publishing); Mauna Kea Technologies, MiMedx Group, Titan Medical (Consultant/Advisor).
John S. Wiener, MD Associate Professor of Surgery (Urology) and Pediatrics; Head, Section of Pediatric Urology, Vice-Chief, Division of Urologic Surgery, Duke University Medical Center, Durham NC. Eli Lilly (Consultant).
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AUA takes responsibility for the content, quality, and scientific integrity of this CME activity.
Credit Designation Statement: The American Urological Association designates this educational activity for a maximum of 20.0 AMA PRA Category 1 Credits™. Each physician should only claim credit commensurate with the extent of their participation in the activity.
Estimated time for study, test completion, and reference reading for each SASP is 20 hours.
Original Release Date: January 2015
Expiration Date: December 2018
Target Audience: This self-assessment program is designed for practicing urologists, Board candidates, and/or residents.
Purpose/Need: Urologists and other health care providers need to assess their knowledge of urology. Identified gaps in this knowledge can lead to individualized, practical educational activities, which will result in improved patient care.
Method of Participation: Participants have access to the SASP through the Qstream website and emails. The SASP is designated for a maximum of 20 AMA PRA Category 1 Credits™. To earn credit, participants must read the educational material provided, answering 100% of the test questions correctly, and complete the online evaluation.
Media Used: Online and email
Learning Objectives: After completion of this continuing medical education activity, including this examination, participants will be able to:
- assess their knowledge of urology
- demonstrate an increased knowledge base of urology
- apply increased knowledge to improve quality of patient care
- evaluate strengths and weaknesses in urology upon review of their personalized participant profile
- develop a personalized study program
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Disclaimer: The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction Permission: The material contained in this examination is protected under U.S. Copyright law. Duplication of any part of this examination by any means including, but not limited to, photographic reproduction is a FEDERAL OFFENSE.